Champions Oncology, Inc. (NASDAQ: CSBR) – Q2 2026 Earnings
Champions Oncology, Inc. (NASDAQ: CSBR) – Q2 2026 Earnings
Press release and earnings call link
Earnings Release Date: Dec. 15, 2025
Stock Price: $6.72
Market Cap: $92.6 million
Q2 2026 sales of $15.0 million vs $13.5 million in the prior year
Q2 2026 GAAP Diluted EPS of $0.02 vs $0.05 in the prior year
Overview:
Champions Oncology is a contract research organization (CRO) focused on oncology drug development. It provides preclinical testing services and increasingly monetizes proprietary biological and genomic data.
Revenue drivers:
Core revenue comes from oncology services such as patient-derived xenograft (PDX) models (tumors grown in mice to test drug efficacy), pharmacology studies, and related lab services. A secondary and growing driver is its data platform, which licenses curated biological and sequencing data to biopharma companies.
Customer base / end markets:
Mid-sized and large pharmaceutical companies and venture-backed biotech firms conducting oncology research.
Market positioning:
A niche, differentiated oncology-focused CRO with one of the largest annotated PDX tumor banks and rare in-house radiolabeling capabilities (radioactive tagging of compounds for imaging and drug development).
Recent financial trajectory:
After a prolonged biotech funding downturn, the company has returned to modest growth, posting 11% year-over-year revenue growth in Q2 FY2026 and materially improved gross margins. Profitability is fragile but trending positive on an adjusted EBITDA basis.
Key near-term themes:
Operational discipline, margin expansion from reduced outsourcing, scaling radiolabeling services, and long-term optionality from the data platform and Corellia subsidiary.
Competitive Advantage Insights
Press Release vs Call Transcript Comparison
The press release presents a clean recovery narrative centered on margins and EBITDA stability. The earnings call reframes the company as being mid-transition: stabilizing its legacy services business while deliberately investing into higher-margin, more scalable data and radiopharmaceutical workflows. This difference matters because valuation hinges on whether CSBR is seen as a cyclical CRO or a hybrid services-plus-data platform.
Positive Insights
Negative Insights
Investor Underappreciation Signals
✅Radiolabeling insourcing leverage — Radiolabeling demand is rising, but margins are temporarily depressed by outsourced costs; investors may miss that bringing this work fully in-house could mechanically lift gross margins without incremental revenue growth.
✅Booking quality normalization — Revenue growth is being driven by fewer cancellations rather than aggressive new sales, a subtle but important sign that customer funding health is improving faster than headline biotech sentiment suggests.
✅Corellia P&L overhang — Ongoing losses from Corellia obscure the profitability of the core business, and external funding could cleanly separate optionality from reported earnings.
✅Data platform leadership upgrade — The hiring of a dedicated GM with Illumina and consulting background signals a shift from experimentation to commercialization that is not obvious from the press release alone.
Tariff Risk
No mentions of U.S. tariffs or trade policy impacts in the transcript—no discussion of supply chain, pricing actions, customer demand shifts, or mitigation steps tied to tariffs.
Hot Stock Trends Analysis
Previous Earnings Call
Quarter-over-quarter comparison (Previous Analysis)
Q1 FY2026 tells the story of a company coming off a trough. Management is focused on stabilizing operations, proving cancellations are easing, rebuilding confidence after Q4 softness, and laying the groundwork for radiopharma and data initiatives while navigating a difficult funding environment.Q2 FY2026 advances that story into one of early execution and leverage. Management shifts from “are we through the worst?” to “how do we scale responsibly?” The narrative becomes more disciplined and forward-looking, with clearer margin expectations, a defined capital allocation framework, and growing confidence that Champions can self-fund growth while positioning itself as a differentiated oncology services and data platform.
Year-over-year comparison
Q2 FY2025 presents Champions Oncology as a company emerging from volatility, focused on stabilizing operations, restoring profitability, and unlocking latent value in its data assets. The narrative is about regaining footing and convincing investors that the rebound is real.
Q2 FY2026 advances that story into one of controlled execution and leverage. Management now speaks as if the turnaround phase has largely passed. The emphasis shifts to scaling a differentiated platform, managing capital deliberately, and positioning the company for sustained growth without shareholder dilution.
Final Takeaway
Champions Oncology is in a stabilization-to-reacceleration phase, focusing on operational leverage in core oncology services while investing in radiolabeling/radiopharma workflows and a higher-value data platform. While conversion improvement and 50%+ core margins are encouraging, there are concerns about near-term OpEx drag and the uncertain timeline/disclosure around Corellia funding and value. Execution on repeatable margins, data commercialization, and radiolabeling insourcing will be critical for future performance. Verdict: Hold, with upside if these initiatives translate into measurable bookings and sustained profitability.